Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer

NCT00496756 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

14

Enrollment

OTHER

Sponsor class

Stopped Low accrual rate

Conditions

Kidney Cancer

Interventions

DRUG: Sorafenib

Sponsor

University of Nebraska

Collaborators

[object Object]
[object Object]